Epithalon vs MOTS-c
Both peptides are investigated in aging-biology research, but they engage different biological axes. Epithalon targets the pineal-gland and telomerase-activity axis studied primarily in Russian gerontology. MOTS-c targets the mitochondrial-to-nuclear signalling axis studied primarily in metabolic-homeostasis research. This page summarises how the published research separates them.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Origin | Synthetic tetrapeptide analogue of an endogenous pineal-gland peptide | 16-residue peptide encoded within the 12S rRNA gene of mitochondrial DNA |
| Structural class | Tetrapeptide (Ala-Glu-Asp-Gly) | 16-residue mitochondrial-derived peptide |
| Best-studied mechanism | Telomerase-activity modulation, pineal-gland function, lifespan endpoints | AMPK pathway activation, metabolic homeostasis, exercise-mimetic biology |
| Research tradition | Russian gerontology (Anisimov, Khavinson laboratories) | Western metabolic biology (Lee, Reynolds, Kim laboratories) |
| Primary model systems | Murine and Drosophila lifespan studies, neuronal differentiation in vitro | Murine high-fat-diet metabolic studies, skeletal-muscle AMPK activation |
| Clinical evidence | Small number of Russian clinical-pilot reports (not Phase 1 by Western standards) | No published clinical trials |
| Ronin catalog vial size | 10 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
Epithalon was developed in Russian gerontology research as a synthetic analogue of an endogenous pineal-gland peptide. The published mechanistic literature concentrates on telomerase-activity modulation and on lifespan-extension endpoints in murine and Drosophila models. The Anisimov laboratory published the seminal lifespan studies in Swiss-derived SHR mice with chronic multi-month dosing at low microgram-per-animal doses. A secondary line of investigation examines neuronal-differentiation and neurotrophic-factor effects.
MOTS-c was characterised as a mitochondrial-derived peptide whose coding sequence lies within the 12S rRNA gene of mitochondrial DNA. The published mechanistic literature centres on AMPK pathway activation in skeletal muscle and on metabolic-homeostasis effects (insulin sensitivity, glucose tolerance, adiposity reduction) in high-fat-diet murine models. The exercise-mimetic framing positions MOTS-c as a regulator of age-dependent physical decline.
The aging-biology framing is the shared territory, but the biological axes are different: pineal-gland / telomerase for Epithalon, mitochondrial-to-nuclear signalling / AMPK for MOTS-c. Combined-administration studies are absent from the published literature, and the two compounds are read by different research sub-communities within the aging-biology field.
How research has examined each
The Epithalon literature is concentrated in Russian gerontology journals and in the Khavinson and Anisimov research outputs. Lifespan studies in mice (Anisimov 2003) and Drosophila (Khavinson 2000), neuronal-differentiation work (Khavinson 2019), and peptide-regulation-of-proliferative-activity studies (Khavinson 2022) form the core of the published research.
The MOTS-c literature is concentrated in Western metabolic-biology journals. The Lee 2015 Cell Metabolism paper establishing the metabolic-homeostasis phenotype, the Reynolds 2021 Nature Communications paper characterising the exercise-induced biology, and the Kim 2019 work on plasma metabolites form the core of the published research.
The two literatures do not cite one another. They occupy different research traditions, different journals, and different conceptual frameworks within the aging-biology field. Survey reviews of anti-aging interventions may mention both alongside calorie restriction, rapamycin, and NAD+-pool strategies, but the primary research outputs are non-overlapping.
Stacking considerations in research contexts
The two compounds are not commonly co-administered in published research protocols. Their biological axes (pineal/telomerase versus mitochondrial/AMPK) are distinct enough that a combined-administration protocol would need a specific aging-biology hypothesis that neither compound alone could address. Both are available as separate lyophilised vials in the Ronin catalog.
Sourcing both at Ronin
Both compounds ship as 10 mg lyophilised peptide in glass vials with certificate-of-analysis documentation. The Epithalon vial page and the MOTS-c vial page carry per-compound spec sheets. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.
Frequently asked research questions
Are they both ‘anti-aging peptides’?
Both are investigated in aging-biology research, but they engage different axes: Epithalon targets pineal-gland / telomerase biology; MOTS-c targets mitochondrial / AMPK metabolic-homeostasis biology.
Do they come from the same research tradition?
No. Epithalon was developed in Russian gerontology. MOTS-c was characterised in Western metabolic biology. The two literatures do not cite one another.
Has either been tested in human clinical trials?
A small number of Russian clinical-pilot reports exist for Epithalon but do not constitute Phase 1 trials by Western standards. MOTS-c has no published clinical trials.
Are they stacked in research protocols?
Not in the published literature. Their biological axes are distinct enough that combined-administration protocols would need a specific hypothesis.
Are either approved for human use?
Neither is approved by the FDA or Health Canada. Both are research-grade reagents sold strictly for laboratory and bench-research applications.
References
- Khavinson VKh et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development, 2000. [PMID 11087911]
- Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 2003. [PMID 12049808]
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. [PMID 25738459]
- Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline. Nature Communications, 2021. [PMID 33293544]
- Kim SJ et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports, 2019. [PMID 31496140]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.